Feb 25 (Reuters) - ZIOPHARM Oncology Inc :
* ZIOPHARM ONCOLOGY PROVIDES LEADERSHIP AND CORPORATE UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS
* Q4 LOSS PER SHARE $0.11
* Q4 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA
* HEIDI HAGEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER REPLACING DR. LAURENCE COOPER; SEARCH FOR PERMANENT CEO INITIATED
* NET LOSS FOR Q4 OF 2020, WAS $22.8 MILLION, OR $0.11 PER SHARE
* CASH AND CASH EQUIVALENTS, AS OF DECEMBER 31, 2020 WERE $115.1 MILLION
* CASH POSITION IS SUFFICIENT TO FUND COMPANY OPERATIONS INTO Q2 OF 2022
* RECEIVED IND CLEARANCE BY U.S. FDA FOR CO'S TCR-T TRIAL UTILIZING SIX "HOTSPOT" TCRS FROM ITS LIBRARY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.